Oncology News

CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.

CHICAGO — The addition of chemotherapy to endocrine therapy did not extend OS after surgery among older patients with ER-positive, HER2-negative breast cancer with a high tumor genomic grade index.

CHICAGO — Patients aged 55 years or older with low-grade luminal A breast cancer who receive endocrine therapy can safely avoid radiotherapy after breast-conserving surgery, according to a prospective study presented at ASCO Annual Meeting.

Recent findings suggest that with HPV tests, intervals between cervical screenings can be extended to 5 years after a negative result in women aged 25 to 49 years and even longer for women aged older than 50 years.

CHICAGO — Rucaparib monotherapy significantly prolonged PFS compared with placebo in the first-line maintenance setting among women with advanced ovarian cancer, regardless of BRCA mutation and homologous recombination deficiency status.

CHICAGO — Trastuzumab deruxtecan exhibited a tolerable safety profile with longer follow-up among patients with HER2-positive unresectable and/or metastatic breast cancer in the DESTINY-Breast03 trial, a study at ASCO Annual Meeting showed.

Eleanora Teplinsky, MD (@drteplinsky). June 5, 2022. Standing ovation for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22. [Video in original post.] Twitter.

CHICAGO — Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.